mdg-annual-report-2013

10 KapitelT … as in THERAPEUTIC APPROACHESHigh potential drug projects. Medigene has one drug on the market, Veregen®,and several drug projects in different stages of development. The clinical drug candidates endoTAG®-1and RhuDex® are in development for the treatment of cancer and autoimmune diseases. Three newimmunotherapy platforms recently acquired, providing cutting-edge therapies with programs in clinicaland preclinical development to treat various types of tumour, will complement Medigene’s advanceddrug pipeline. By focusing on these approaches in immunotherapy, Medigene creates positive long-termprospects. According to expert estimates, in ten years’ time more than 60% of all types of cancer will betreated on the basis of immunotherapy. The total market for these therapies may then amountto US$ 35 billion – for drugs which facilitate improved treatment optionsfor seriously ill patients.